{"id":2748,"date":"2017-09-23T05:46:34","date_gmt":"2017-09-23T03:46:34","guid":{"rendered":"https:\/\/eae.gr\/uncategorized\/amyloeidosi\/"},"modified":"2024-07-27T00:21:16","modified_gmt":"2024-07-26T22:21:16","slug":"amyloeidosi","status":"publish","type":"post","link":"https:\/\/eae.gr\/en\/active-clinical-studies-en\/amyloeidosi\/","title":{"rendered":"\u0391\u039c\u03a5\u039b\u039f\u0395\u0399\u0394\u03a9\u03a3\u0397"},"content":{"rendered":"<p><strong><span class=\"study-overview-item-text\">CR109160 \/ <\/span>AQUARIUS\u00a0 A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis<\/strong><\/p>\n<p><strong>\u039f\u03b9 \u03b1\u03c3\u03b8\u03b5\u03bd\u03b5\u03af\u03c2 \u03c4\u03c5\u03c7\u03b1\u03b9\u03c0\u03bf\u03b9\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03b1\u03bd \u03bb\u03ac\u03b2\u03bf\u03c5\u03bd \u03b5\u03af\u03c4\u03b5 Dare-VCD \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03b1\u03c1\u03c7\u03ae \u03b5\u03af\u03c4\u03b5 Daratumumab \u03b3\u03b9\u03b1 3 \u03ba\u03cd\u03ba\u03bb\u03bf\u03c5\u03c2 \u03ba\u03b1\u03b9 \u03c0\u03c1\u03bf\u03c3\u03b8\u03ae\u03ba\u03b7 VCD\u03c3\u03c4co4d1<\/strong><\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0395\u039d\u03a4\u0391\u039e\u0397\u03a3<\/strong><br \/>\n\u2022 \u039a\u03b1\u03c1\u03b4\u03b9\u03b1\u03ba\u03ae \u03c3\u03c5\u03bc\u03bc\u03b5\u03c4\u03bf\u03c7\u03ae \u03bc\u03b5 MWT&amp;gt; 12mm \u03c3\u03b5 \u03c5\u03c0\u03ad\u03c1\u03b7\u03c7\u03bf \u03ba\u03b1\u03c1\u03b4\u03af\u03b1\u03c2 \u03ae NTproBNP332pg\/mL (\u03c3\u03b5 \u03b1\u03c3\u03b8\u03b5\u03bd\u03b5\u03af\u03c2 \u03c7\u03c9\u03c1\u03af\u03c2 \u03b5\u03c0\u03b7\u03c1\u03b5\u03b1\u03c3\u03bc\u03ad\u03bd\u03b7 \u03bd\u03b5\u03c6\u03c1\u03b9\u03ba\u03ae \u03bb\u03b5\u03b9\u03c4\u03bf\u03c5\u03c1\u03b3\u03af\u03b1 \u03ae \u03bc\u03cc\u03bd\u03b9\u03bc\u03b7\u03ba\u03bf\u03bb\u03c0\u03b9\u03ba\u03ae \u03bc\u03b1\u03c1\u03bc\u03b1\u03c1\u03c5\u03b3\u03ae)<br \/>\n\u2022 Mayo stage 2 \u03ae 3\u0391<br \/>\n\u2022 \u039c\u03b5\u03c4\u03c1\u03ae\u03c3\u03b9\u03bc\u03b7 \u03bd\u03cc\u03c3\u03bf\u03c2 \u03bc\u03b5 dFLC&amp;gt; 40mg\/L<br \/>\n\u2022 eGFR &amp;gt; 20mL\/min\/1.73m 2 (CKD-EPI)<\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0391\u03a0\u039f\u039a\u039b\u0395\u0399\u03a3\u039c\u039f\u03a5<\/strong><br \/>\n\u2022 \u03a3\u03c5\u03bc\u03c0\u03c4\u03c9\u03bc\u03b1\u03c4\u03b9\u03ba\u03cc \u03bc\u03c5\u03ad\u03bb\u03c9\u03bc\u03b1 \u03bc\u03b5 SLiMCRAB<br \/>\n\u2022 NTproBNP&amp;gt;8500pg\/mL<br \/>\n\u2022 HbsAg (+) \u03ae Anti-Hbc (+)\/HbsAg(-)\/HBV-DNA (+)<br \/>\n\u2022 \u03a3\u03c5\u03bc\u03c0\u03c4\u03c9\u03bc\u03b1\u03c4\u03b9\u03ba\u03ae \u03bf\u03c1\u03b8\u03bf\u03c3\u03c4\u03b1\u03c4\u03b9\u03ba\u03ae \u03c5\u03c0\u03cc\u03c4\u03b1\u03c3\u03b7 (\u03c0\u03b1\u03c1\u03ac \u03c4\u03b7\u03bd \u03bb\u03ae\u03c8\u03b7 \u03b1\u03b3\u03c9\u03b3\u03ae\u03c2) \u03ae \u03a3\u0391\u03a0 &amp;lt; 90mmHg<\/p>\n<p><strong><em>\u039a\u0395\u039d\u03a4\u03a1\u0391 \u03a0\u039f\u03a5 \u03a3\u03a5\u039c\u039c\u0395\u03a4\u0395\u03a7\u039f\u03a5\u039d:<\/em><\/strong><br \/>\n\u2022 \u0398\u0395\u03a1\u0391\u03a0\u0395\u03a5\u03a4\u0399\u039a\u0397 \u039a\u039b\u0399\u039d\u0399\u039a\u0397, \u039d\u039f\u03a3\u039f\u039a\u039f\u039c\u0395\u0399\u039f \u00ab\u0391\u039b\u0395\u039e\u0391\u039d\u0394\u03a1\u0391\u00bb, \u0391\u0398\u0397\u039d\u0391, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03a3\u03c4. \u039a\u03b1\u03c3\u03c4\u03c1\u03af\u03c4\u03b7\u03c2<\/p>\n<hr \/>\n<p><strong>AFFIRM-AL A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects With Light Chain (AL) Amyloidosis<\/strong><\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0395\u039d\u03a4\u0391\u039e\u0397\u03a3<\/strong><br \/>\n\u2022 \u039d\u03ad\u03b1 \u03b4\u03b9\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7 AL \u03b1\u03bc\u03c5\u03bb\u03bf\u03b5\u03b5\u03af\u03b4\u03c9\u03c3\u03b7\u03c2 Mayo stage 2012 IV (dFLC&amp;gt;180 PLUS hsTnT&amp;gt;40 PLUS NTproBNP&amp;gt;1800)<br \/>\n\u2022 \u039a\u03b1\u03c1\u03b4\u03b9\u03b1\u03ba\u03ae \u03c3\u03c5\u03bc\u03bc\u03b5\u03c4\u03bf\u03c7\u03ae \u03bc\u03b5 MWT&amp;gt; 12mm \u03c3\u03b5 \u03c5\u03c0\u03ad\u03c1\u03b7\u03c7\u03bf \u03ba\u03b1\u03c1\u03b4\u03af\u03b1\u03c2<br \/>\n\u2022 6MWT \u03b1\u03c0\u03cc\u03c3\u03c4\u03b1\u03c3\u03b7 \u03bc\u03b5\u03c4\u03b1\u03be\u03cd 30-550m<br \/>\n\u2022 eGFR&amp;gt; 30 ml\/min\/1.73m 2 (CKD-EPI)<br \/>\n\u2022 \u0391\u03c1\u03c7\u03b9\u03ba\u03ae \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03bc\u03b5 \u03b2\u03ac\u03c3\u03b7 \u03c4\u03bf bortezomib (\u03b5\u03c0\u03b9\u03c4\u03c1\u03ad\u03c0\u03b5\u03c4\u03b1\u03b9 \u03c4\u03bf daratumumab)<\/p>\n<p><span style=\"text-decoration: underline;\">\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0391\u03a0\u039f\u039a\u039b\u0395\u0399\u03a3\u039c\u039f\u03a5:<\/span><br \/>\n\u2022 NTproBNP&amp;gt;8500pg\/mL<br \/>\n\u2022 \u0395\u03bd\u03b5\u03c1\u03b3\u03cc\u03c2 \u03b7\u03c0\u03b1\u03c4\u03af\u03c4\u03b9\u03b4\u03b1 B \u03ae C \u03ae HIV<br \/>\n\u2022 \u0394\u03b9\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7 \u03c3\u03c5\u03bc\u03c0\u03c4\u03c9\u03bc\u03b1\u03c4\u03b9\u03ba\u03bf\u03cd \u03c0\u03bf\u03bb\u03bb\u03b1\u03c0\u03bb\u03bf\u03cd \u03bc\u03c5\u03b5\u03bb\u03ce\u03bc\u03b1\u03c4\u03bf\u03c2 \u03bc\u03b5 SLiMCRAB<br \/>\n\u2022 \u03a3\u03c5\u03bc\u03c0\u03c4\u03c9\u03bc\u03b1\u03c4\u03b9\u03ba\u03ae \u03bf\u03c1\u03b8\u03bf\u03c3\u03c4\u03b1\u03c4\u03b9\u03ba\u03ae \u03c5\u03c0\u03cc\u03c4\u03b1\u03c3\u03b7 (\u03c0\u03b1\u03c1\u03ac \u03c4\u03b7\u03bd \u03bb\u03ae\u03c8\u03b7 \u03b1\u03b3\u03c9\u03b3\u03ae\u03c2) \u03ae \u03a3\u0391\u03a0 &amp;lt; 90mmHg<\/p>\n<p><em><strong>\u00a0\u039a\u0395\u039d\u03a4\u03a1\u0391 \u03a0\u039f\u03a5 \u03a3\u03a5\u039c\u039c\u0395\u03a4\u0395\u03a7\u039f\u03a5\u039d:<\/strong><\/em><\/p>\n<p><em>\u2022 \u0398\u0395\u03a1\u0391\u03a0\u0395\u03a5\u03a4\u0399\u039a\u0397 \u039a\u039b\u0399\u039d\u0399\u039a\u0397, \u039d\u039f\u03a3\u039f\u039a\u039f\u039c\u0395\u0399\u039f \u00ab\u0391\u039b\u0395\u039e\u0391\u039d\u0394\u03a1\u0391\u00bb, \u0391\u0398\u0397\u039d\u0391, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03a3\u03c4. \u039a\u03b1\u03c3\u03c4\u03c1\u03af\u03c4\u03b7\u03c2<\/em><br \/>\n<em>\u2022\u03a0\u0391\u039d\u0395\u03a0\u0399\u03a3\u03a4\u0397\u039c\u0399\u039f \u03a0\u0391\u03a4\u03a1\u0391\u03a3<\/em><br \/>\n<em>\u2022\u039d\u039f\u03a3\u039f\u039a\u039f\u039c\u0395\u0399\u039f \u0398\u0395\u0391\u0393\u0395\u039d\u0395\u0399\u039f, \u0398\u0395\u03a3\u03a3\u0391\u039b\u039f\u039d\u0399\u039a\u0397<\/em><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>CR109160 \/ AQUARIUS\u00a0 A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis \u039f\u03b9 \u03b1\u03c3\u03b8\u03b5\u03bd\u03b5\u03af\u03c2 \u03c4\u03c5\u03c7\u03b1\u03b9\u03c0\u03bf\u03b9\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03b1\u03bd \u03bb\u03ac\u03b2\u03bf\u03c5\u03bd \u03b5\u03af\u03c4\u03b5 Dare-VCD<span class=\"excerpt-hellip\"> [\u2026]<\/span><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[178],"tags":[],"class_list":["post-2748","post","type-post","status-publish","format-standard","hentry","category-active-clinical-studies-en"],"_links":{"self":[{"href":"https:\/\/eae.gr\/en\/wp-json\/wp\/v2\/posts\/2748","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/eae.gr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eae.gr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eae.gr\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/eae.gr\/en\/wp-json\/wp\/v2\/comments?post=2748"}],"version-history":[{"count":1,"href":"https:\/\/eae.gr\/en\/wp-json\/wp\/v2\/posts\/2748\/revisions"}],"predecessor-version":[{"id":2752,"href":"https:\/\/eae.gr\/en\/wp-json\/wp\/v2\/posts\/2748\/revisions\/2752"}],"wp:attachment":[{"href":"https:\/\/eae.gr\/en\/wp-json\/wp\/v2\/media?parent=2748"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eae.gr\/en\/wp-json\/wp\/v2\/categories?post=2748"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/eae.gr\/en\/wp-json\/wp\/v2\/tags?post=2748"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}